Takeda deploys Weave Bio’s AI Regulatory Platform across 14 active global drug programs
The collaboration combines Weave Bio’s artificial intelligence tools with Takeda’s regulatory expertise to simplify and speed up activities involved in preparing submissions and responding to questions from health authorities.
JAPAN—Takeda has partnered with Weave Bio to deploy the biotechnology company’s AI-powered regulatory automation platform across 14 ongoing drug development programmes in markets worldwide.
The collaboration combines Weave Bio’s artificial intelligence tools with Takeda’s regulatory expertise to simplify and speed up activities involved in preparing submissions and responding to questions from health authorities.
AI supports regulatory submissions
The partnership initially focused on using AI to support the preparation of investigational new drug (IND) submissions.
Takeda and Weave Bio have since expanded the technology’s use to include health authority questions (HAQs) and responses to those questions (RTQs).
According to a research paper jointly authored by scientists from the two companies, using AI in the evaluated IND workflow reduced the time needed to prepare an initial submission by 97%.
The process took about three hours compared with approximately 100 hours when completed using the conventional approach.
The companies have also assessed the platform’s performance in handling HAQs and RTQs.
In the dataset evaluated, the system processed more than 100 questions without recording extraction errors.
It also achieved an average AI generated answer quality score of 68%, within the companies’ target range of 50% to 70%.
Takeda said the technology is designed to support regulatory professionals rather than replace their role in reviewing and approving regulatory content.
Focus on responsible AI
Takeda Chief Regulatory Officer and Global Regulatory Affairs Head Nahid Latif said the company wants to strengthen the responsible use of AI across its research and development activities.
“We are working to become a leader in the responsible application of AI across every area of R&D,” Latif said.
He added that the collaboration with Weave Bio demonstrates how AI can support regulatory workflows while leaving regulatory professionals responsible for content, verification and final decisions.
The partnership comes as regulators worldwide develop clearer expectations for using AI in drug development.
Key areas of focus include patient safety, validation of AI systems and human oversight.
In January 2025, the US Food and Drug Administration (FDA) issued draft guidance on the use of AI to support regulatory decision-making.
A year later, the FDA and European Medicines Agency (EMA) published joint guiding principles addressing the responsible use of AI in medicines regulation.
Takeda and Weave Bio said their approach is designed to align with these emerging regulatory expectations, particularly the need for appropriate human oversight.
Takeda advances narcolepsy treatment
The collaboration follows another recent development for Takeda in Japan.
Last month, the company received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orzeyful (oveporexton), a treatment for narcolepsy type 1 in adults.
Takeda continues to expand the use of AI across its drug development activities as the pharmaceutical industry adopts new technologies to support research, regulatory operations, and the delivery of medicines to patients.
Be the first to leave a comment